• Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Zhang Y, Hill J, Bissonnette RP, Medina D, Brown PH, Aldaz CM 2008 Transcriptomic signature of the chemopreventive bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models. BMC Med. Genomics 1: 40. *

• Abir F, Alva S, Kaminski DL, Longo WE 2005 The role of arachidonic acid regulatory enzymes in colorectal disease. Dis. Colon Rectum 48: 1471-1483. *

• Abu J, Batuwangala M, Herbert K, Symonds P 2005 Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol. 6: 712-720.

• Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB 2006 Anticancer potential of silymarin: from bench to bed side. Anticancer Res. 26: 4457-4498.

• Aggarwal BB, Takada Y, Oommen OV 2004 From chemoprevention to chemotherapy: common targets and common goals. Expert Opin. Investig. Drugs 13: 1327-1338.

• Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Feng Z, Bronner MP 2000 The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 157: 737-745. *

• Agoston ES, Hatcher MA, Kensler TW, Posner GH 2006 Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med. Chem. 6: 53-71.

• Ahmadi AA, Polyak S 2007 Endoscopy/surveillance in inflammatory bowel disease. Surg. Clin. North Am. 87: 743-762.

• Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD 2006 Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int. J. Cancer 119: 2958-2969. *

• Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P; Phoenix and Tucson Gastroenterologist Networks 2005 Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J. Natl. Cancer Inst. 97: 846-853. *

• Allgayer H 2003 Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 Suppl. 2: 10-14. *

• Allgayer H, Kruis W 2006 Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 4: 521.

• Allgayer H, Kruis W 2003 PPAR-ligands: a clinically important regulatory system with multiple options in the treatment of diabetes mellitus, inflammatory bowel disease and in the chemoprevention of colon cancer? Z. Gastroenterol. 41: 1035-1038.

• Anderson WF, Umar A, Viner JL, Hawk ET 2002 The role of cyclooxygenase inhibitors in cancer prevention. Curr. Pharm. Des. 8: 1035-1062.

• Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44.

• Arber N, DuBois RN 1999 Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr. Gastroenterol. Rep. 1: 441-448.

• Arber N, Levin B 2008 Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 134: 1224-1237. *

• Badawi AF, Badr MZ 2002 Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Int. J. Oncol. 20: 1109-1122.

• Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, Mishina Y, Martin DW, Shoieb A, McEntee MF, Eling TE 2006 Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131: 1553-1560. *

• Baek SJ, Wilson LC, Lee CH, Eling TE 2002 Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacol. Exp. Ther. 301: 1126-1131. *

• Bai L, Kao JY, Law DJ, Merchant JL 2006 Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection. Gastroenterology 131: 841-852. *

• Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, Dipaola RS, Abate-Shen C 2006 Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clin. Cancer Res. 12: 5895-5901. *

• Band PR, Besner JG, Leclaire R, Girard C, Diorio G, Deschamps M, Gélinas M, Larochelle D 1982 Phase I study of 13-cis-retinoic acid toxicity. Cancer Treat. Rep. 66: 1759-1761.

• Bandhuvula P, Saba JD 2007 Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. Trends Mol. Med. 13: 210-217. *

• Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L et al 2003 A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348: 891-899. *

• Baron JA, Sandler RS 2000 Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 51: 511-523. *

• Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG 2006 A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131: 1674-1682. *

• Bartsch H, Nair J 2005 Accumulation of lipid peroxidation-derived DNA lesions: potential lead markers for chemoprevention of inflammation-driven malignancies. Mutat. Res. 591: 34-44.

• Bartsch H, Nair J 2004 Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect. Prev. 28: 385-391.

• Befeler AS 2003 New developments in hepatocellular carcinoma. 54th Annual Meeting of the American Association for the Study of Liver Diseases.

• Benamouzig R, Chaussade S 2002 Chemoprevention of colorectal cancer. Presse. Med. 31: 124-127.

• Beno I, Klvanova J, Magalova T, Brtkova A 2000 Blood levels of natural antioxidants in gastric and colorectal precancerous lesions and cancers in Slovakia. Neoplasma 47: 37-40.

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020. *

• Bernstein CN 2006 Biomarkers, surveillance strategies, chromoendoscopy medication-induced malignancies and chemoprevention (past). Inflamm. Bowel Dis. 12 Suppl. 3: S10-S11.

• Bernstein CN 2006 Neoplasia in inflammatory bowel disease: surveillance and management strategies. Curr. Gastroenterol. Rep. 8: 513-518.

• Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH 2002 Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm. Bowel Dis. 8: 356-361. *

• Bertagnolli MM 1999 Cyclooxygenase-2 as a target for prevention of colorectal cancer. Curr. Oncol. Rep. 1: 173-178.

• Bertagnolli MM 2007 Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol. 8: 439-443.

• Biasco G, Di Marco MC 2005 Folate and prevention of colorectal cancer in ulcerative colitis. Eur. J Cancer Prev. 14: 395-398.

• Biasco G, Zannoni U, Paganelli GM, Santucci R, Gionchetti P, Rivolta G, Miniero R, Pironi L, Calabrese C, Di Febo G, Miglioli M 1997 Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Cancer Epidemiol. Biomarkers Prev. 6: 469-471.

• Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, Peters JM 2008 Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits chemically-induced skin tumorigenesis. Carcinogenesis Sep 17 [Epub ahead of print]. *

• Boberg KM, Schrumpf E 2004 Diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 6: 52-59.

• Bogos K, Renyi-Vamos F, Kovacs G, Tovari J, Dome B 2008 Role of retinoic receptors in lung carcinogenesis. J. Exp. Clin. Cancer Res. 27: 18.

• Boland CR 2004 Biology of cancer in ulcerative colitis and consequences for chemoprevention. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 82-83. May 7-8. *

• Bollheimer LC, Buettner R, Kullmann A, Kullmann F 2005 Folate and its preventive potential in colorectal carcinogenesis. How strong is the biological and epidemiological evidence? Crit. Rev. Oncol. Hematol. 55: 13-36.

• Bommareddy A, Arasada BL, Mathees DP, Dwivedi C 2006 Chemopreventive effects of dietary flaxseed on colon tumor development. Nutr. Cancer 54: 216-222. *

• Bonovas S, Filioussi K, Sitaras NM 2005 Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br. J. Clin. Pharmacol. 60: 194-203. *

• Boone WT 1998 Colorectal cancer - chemoprevention. J. Miss. State Med. Assoc. 39: 318-322.

• Borutinskaite VV, Navakauskiene R, Magnusson KE 2006 Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Ann. N. Y. Acad. Sci. 1091: 346-355. *

• Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ 2006 Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 27: 2371-2382. *

• Brabender J, Metzger R, Salonga D, Danenberg KD, Danenberg PV, Holscher AH, Schneider PM 2005 Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis 26: 525-530. *

• Brand R 2001 The potential chemoprotective effect of ursodiol. Am. J. Gastroenterol. 96: 1687. *

• Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, Oksanen A, Ericzon B-G, Hockerstedt K, Makisalo H, Kirkegaard P, Friman S, Bjoro K, Schrumpf E 2004 Chemopreventive effect of URSO in primary sclerosing cholangitis? Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 78. June 18-19. *

• Brasitus TA 1995 Primary chemoprevention strategies for colorectal cancer: ursodeoxycholic acid and other agents. Gastroenterology 109: 2036-2038. *

• Brazowski E, Rozen P, Misonzhnick-Bedny F, Gitstein G 2005 Characteristics of familial juvenile polyps expressing cyclooxygenase-2. Am. J. Gastroenterol. 100: 130-138. *

• Brentnall T 2003 UC for UC: ursodiol chemoprevention for ulcerative colitis. Inflamm. Bowel Dis. 9: 338. *

• Brentnall TA 2003 Ursodiol: good drug makes good. Gastroenterology 124: 1139-1140. *

• Bresalier RS 2008 Chemoprevention of colorectal cancer: why all the confusion? Curr. Opin. Gastroenterol. 24: 48-50. *

• Bresalier RS 2007 Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story). Curr. Opin. Gastroenterol. 23: 44-47.

• Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast R, Zou C 2006 4-HPR modulates gene expression in ovarian cells. Int. J. Cancer 119: 1005-1013. *

• Brinckerhoff CE, Sporn MB 2003 Retinoids and rexinoids for the 21st century: a brave new world for arthritis. J. Rheumatol. 30: 211-213.

• Briskey EN, Pamies RJ 2000 Colorectal cancer: update on recent advances and their impact on screening protocols. J. Natl. Med. Assoc. 92: 222-230.

• Bronner MP 2006 Biomarkers, surveillance strategies, chromoendoscopy medication-induced malignancies and chemoprevention (present). Inflamm. Bowel Dis. 12 Suppl. 3: S11-S12.

• Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A, O'Brien PE 2000 5-Aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig. Dis. Sci. 45: 1578-1584. *

• Brtko J 2007 Role of retinoids and their cognate nuclear receptors in breast cancer chemoprevention. Cent. Eur. J. Public Health 15: 3-6.

• Brtko J 2007 Retinoids, rexinoids and their cognate nuclear receptors: character and their role in chemoprevention of selected malignant diseases. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 151: 187-194. *

• Bull AW 2003 The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch. Pathol. Lab. Med. 127: 1121-1123. *

• Burk RF 2001 Selenium: recent clinical advances. Curr. Opin. Gastroenterol. 17: 162-166.

• Burke CA, Bauer WM, Lashner B 2003 Chemoprevention of colorectal cancer: slow, steady progress. Cleve. Clin. J. Med. 70: 346-350. *

• Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldof H, Van Krieken JH, Griffioen G 1999 Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment. Pharmacol. Ther. 13: 1397-1402. *

• Bus PJ, Verspaget HW, Lamers CB, Griffioen G 2000 Chemoprevention of colorectal cancer by non-steroidal anti-inflammatory drugs. Scand. J. Gastroenterol. Suppl. 232: 101-104.

• Calabrese V, Butterfield DA, Stella AM 2003 Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease. Ital. J. Biochem. 52: 177-181.

• Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA 2003 Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25: 437-444. *

• Caputo M, Eletto D, Torino G, Tecce MF 2008 Cooperation of docosahexaenoic acid and vitamin E in the regulation of UDP-glucuronosyltransferase mRNA expression. J. Cell Physiol. 215: 765-770. *

• Cendan JC, Behrns KE 2007 Associated neoplastic disease in inflammatory bowel disease. Surg. Clin. North Am. 87: 659-672.

• Chan AO, Rashid A 2006 CpG island methylation in precursors of gastrointestinal malignancies. Curr. Mol. Med. 6: 401-408.

• Chan AT 2003 Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 14: 413-418. *

• Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WC, Fuchs CS 2004 A prospective study of aspirin use and the risk for colorectal adenoma. Ann. Intern. Med. 140: 157-166. *

• Chan EP, Lichtenstein GR 2006 Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol. Clin. North Am. 35: 675-712.

• Chan TA 2002 Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 3: 166-174.

• Cheng Y, Desreumaux P 2005 5-Aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J. Gastroenterol. 11: 309-314. *

• Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA 2008 Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J. Natl. Cancer Inst. 100: 1223-1232. *

• Chu EC, Chai J, Ahluwalia A, Tarnawski AS 2007 Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment. Pharmacol. Ther. 25: 1443-1449. *

• Chun KS, Surh YJ 2004 Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 68: 1089-1100. *

• Church RD, Fleshman JW, McLeod HL 2003 Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br. J. Surg. 90: 1055-1067. *

• Clapper ML, Chang WC, Meropol NJ 2001 Chemoprevention of colorectal cancer. Curr. Opin. Oncol. 13: 307-313.

• Clapper ML, Cooper HS, Chang WC 2007 Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol. Sin. 28: 1450-1459.

• Clapper ML, Gary MA, Coudry RA, Litwin S, Chang WC, Devarajan K, Lubet RA, Cooper HS 2008 5-Aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 14: 1341-1347.

• Clapper ML, Szarka CE 1998 Glutathione S-transferases - biomarkers of cancer risk and chemopreventive response. Chem. Biol. Interact. 111-112: 377-388.

• Colombo M, Donato MF 2005 Prevention of hepatocellular carcinoma. Semin. Liver Dis. 25: 155-161.

• Conley BA, Ord RA 1996 Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview. J. Craniomaxillofac. Surg. 24: 339-345.

• Conney AH 2004 Tailoring cancer chemoprevention regimens to the individual. J. Cell. Biochem. 91: 277-286. *

• Courtney ED, Matthews S, Finlayson C, Di Pierro D, Belluzzi A, Roda E, Kang JY, Leicester RJ 2007 Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas. Int. J. Colorectal Dis. 22: 765-776. *

• Courtney ED, Melville DM, Leicester RJ 2004 Review article: chemoprevention of colorectal cancer. Aliment. Pharmacol. Ther. 19: 1-24. *

• Croog VJ, Ullman TA, Itzkowitz SH 2003 Chemoprevention of colorectal cancer in ulcerative colitis. Int. J. Colorectal Dis. 18: 392-400. *

• Cross JT, Poole EM, Ulrich CM 2008 A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J. 8: 237-247.

• Cui Y, Lu Z, Bai L, Shi Z, Zhao WE, Zhao B 2007 beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells. Eur. J. Cancer 43: 2590-2601. *

• Dang CT, Shapiro CL, Hudis CA 2002 Potential role of selective COX-2 inhibitors in cancer management. Oncology (Huntingt.) 16: 30-36.

• Dannenberg AJ, Zakim D 1999 Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin. Oncol. 26: 499-504.

• Das D, Arber N, Jankowski JA 2007 Chemoprevention of colorectal cancer. Digestion 76: 51-67.

• Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND, Dougherty ER, Wang N, Lupton JR, Carroll RJ, Chapkin RS 2004 Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res. 64: 6797-6804. *

• de Almeida Vasconcelos Fonseca EM, Chagas CE, Mazzantini RP, Heidor R, Ong TP, Moreno FS 2005 All-trans and 9-cis retinoic acids, retinol and beta-carotene chemopreventive activities during the initial phases of hepatocarcinogenesis involve distinct actions on glutathione S-transferase positive preneoplastic lesions remodeling and DNA damage. Carcinogenesis 26: 1940-1946. *

• Decensi A, Costa A 2000 Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur. J. Cancer 36: 694-709. *

• DeCicco KL, Youngdahl JD, Ross AC 2001 All-trans-retinoic acid and polyriboinosinic : polyribocytidylic acid in combination potentiate specific antibody production and cell-mediated immunity. Immunology 104: 341-348. *

• Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, Buckley AR 2002 Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos. 30: 608-612. *

• Diculescu M, Ciocirlan M, Ciocirlan M, Pitigoi D, Becheanu G, Croitoru A, Spanache S 2003 Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence. Rom. J. Gastroenterol. 12: 283-286.

• Dimagno MJ, Dimagno EP 2007 New advances in acute pancreatitis. Curr. Opin. Gastroenterol. 23: 494-501.

• Dove-Edwin I, Thomas HJ 2001 Review article: the prevention of colorectal cancer. Aliment. Pharmacol. Ther. 15: 323-336. *

• DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA 1998 The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19: 49-53. *

• DuPont HL 2005 Travelers' diarrhea: antimicrobial therapy and chemoprevention. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 191-198. *

• Duvoix A, Delhalle S, Blasius R, Schnekenburger M, Morceau F, Fougere M, Henry E, Galteau MM, Dicato M, Diederich M 2004 Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochem. Pharmacol. 68: 1101-1011. *

• Eaden J 2003 Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 Suppl. 2: 15-21. *

• Eaden J 2004 Colorectal carcinoma and inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 24-30. *

• Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA 1994 Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 54: 5071-5074. *

• Edwards IJ, Sun H, Hu Y, Berquin IM, O'Flaherty JT, Cline JM, Rudel LL, Chen YQ 2008 In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids. J. Biol. Chem. 283: 18441-18449. *

• El-Bayoumy K, Sinha R 2005 Molecular chemoprevention by selenium: a genomic approach. Mutat. Res. 591: 224-236.

• Elder DJ, Halton DE, Hague A, Paraskeva C 1997 Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3: 1679-1683. *

• Elrod HA, Sun SY 2008 PPARgamma and apoptosis in cancer. PPAR Res. 2008: 704165. *

• Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE 2002 ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36: 439-450. *

• Engelbrecht AM, Toit-Kohn JL, Ellis B, Thomas M, Nell T, Smith R 2008 Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model. Apoptosis Sep 11 [Epub ahead of print].

• Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS 2003 Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis 24: 1541-1548. *

• Fardel O, Jigorel E, Le Vee M, Payen L 2005 Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed. Pharmacother. 59: 104-114.

• Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V 2001 Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology 167: 37-46. *

• Ferrandez A, DiSario JA 2002 Hereditary colorectal cancer: screening and management. Curr. Treat. Options Oncol. 3: 459-474.

• Fields AL, Soprano DR, Soprano KJ 2007 Retinoids in biological control and cancer. J. Cell. Biochem. 102: 886-898.

• Fujii S, Fujimori T, Kawamata H, Takeda J, Kitajima K, Omotehara F, Kaihara T, Kusaka T, Ichikawa K, Ohkura Y, Ono Y, Imura J, Yamaoka S, Sakamoto C, Ueda Y, Chiba T 2004 Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut 53: 710-716. *

• Galli A, Mello T, Ceni E, Surrenti E, Surrenti C 2006 The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin. Investig. Drugs 15: 1039-1049.

• Garay CA, Engstrom PF 1999 Chemoprevention of colorectal cancer: dietary and pharmacologic approaches. Oncology (Huntingt.) 13: 89-97.

• Gasche C 2004 The chemoprevention of colorectal carcinoma. Aliment. Pharmacol. Ther. 20 Suppl. 4: 31-35. *

• Gatof D, Ahnen D 2002 Primary prevention of colorectal cancer: diet and drugs. Gastroenterol. Clin. North Am. 31: 587-623, xi.

• Gerhauser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, Liu GY, Sitthimonchai S, Frank N 2003 Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat. Res. 523-524: 163-172.

• Gerner EW, Ignatenko NA, Besselsen DG 2003 Preclinical models for chemoprevention of colon cancer. Recent Results Cancer Res. 163: 58-71.

• Giannini EG, Kane SV, Testa R, Savarino V 2005 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'? Dig. Liver Dis. 37: 723-731.

• Gill S, Sinicrope FA 2005 Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin. Oncol. 32: 24-34. *

• Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR 2003 A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin. Cancer Res. 9: 383-390. *

• Goel A, Kunnumakkara AB, Aggarwal BB 2008 Curcumin as "curecumin": from kitchen to clinic. Biochem. Pharmacol. 75: 787-809. *

• Grau de Castro JJ 2005 COX-2 inhibitors in cancer prevention. Rev. Clin. Esp. 205: 446-456.

• Greenwald P, Kelloff GJ, Boone CW, McDonald SS 1995 Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Cancer Epidemiol. Biomarkers Prev. 4: 691-702. *

• Gross EG, Helfgott MA 1992 Retinoids and the eye. Dermatol. Clin. 10: 521-531.

• Gualdrini UA, Sambuelli A, Barugel M, Gutierrez A, Avila KC 2005 Prevention of colorectal cancer. Acta Gastroenterol. Latinoam. 35: 104-140.

• Gustin DM, Brenner DE 2002 Chemoprevention of colon cancer: current status and future prospects. Cancer Metastasis Rev. 21: 323-348.

• Gwyn K, Sinicrope FA 2002 Chemoprevention of colorectal cancer. Am. J. Gastroenterol. 97: 13-21. *

• Hale LP, Perera D, Gottfried MR, Maggio-Price L, Srinivasan S, Marchuk D 2007 Neonatal co-infection with Helicobacter species markedly accelerates the development of inflammation-associated colonic neoplasia in IL-10(-/-) mice. Helicobacter 12: 598-604. *

• Hameed DA, El-Metwally TH 2008 The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers. Cancer Biol. Ther. 7: 92-100.

• Hanauer SB 2004 Medical therapy for ulcerative colitis 2004. Gastroenterology 126: 1582-1592. *

• Hatcher H, Planalp R, Cho J, Torti FM, Torti SV 2008 Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 65: 1631-1652. *

• Hawk E, Lubet R, Limburg P 1999 Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86: 2551-2563. *

• Hawk ET, Umar A, Viner JL 2004 Colorectal cancer chemoprevention - an overview of the science. Gastroenterology 126: 1423-1447. *

• Hawk ET, Viner JL 2001 Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann. Intern. Med. 134: 158-160. *

• Hayes JD, Kelleher MO, Eggleston IM 2008 The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur. J. Nutr. 47 Suppl. 2: 73-88.

• Heiss E, Herhaus C, Klimo K, Bartsch H, Gerhauser C 2001 Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 276: 32008-32015. *

• Henriksen M, Moum B 2007 Colorectal cancer in inflammatory bowel disease. Tidsskr. Nor. Laegeforen. 127: 2696-2699.

• Herendeen JM, Lindley C 2003 Use of NSAIDs for the chemoprevention of colorectal cancer. Ann. Pharmacother. 37: 1664-1674. *

• Herfarth H 2006 The chemopreventive effect of aminosalicylates. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 47-48. *

• Herfarth H 2002 Colorectal cancer: risk and prevention in inflammatory bowel diseases. Chir. Gastroenterol. 18: 319-324.

• Hess LM, Krutzsch MF, Guillen J, Chow HH, Einspahr J, Batta AK, Salen G, Reid ME, Earnest DL, Alberts DS 2004 Results of a phase I multiple-dose clinical study of ursodeoxycholic acid. Cancer Epidemiol. Biomarkers Prev. 13: 861-867. *

• Hijova E 2005 Matrix metalloproteinases: their biological functions and clinical implications. Bratisl. Lek. Listy. 106: 127-132.

• Hill DL, Grubbs CJ 1982 Retinoids as chemopreventive and anticancer agents intact animals (review). Anticancer Res. 2: 111-124.

• Hisamuddin IM, Wehbi MA, Yang VW 2007 Pharmacogenetics and diseases of the colon. Curr. Opin. Gastroenterol. 23: 60-66.

• Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ 2006 Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res. 12: 2944-2950. *

• Holick MF, Holt PR 2008 Chemoprevention of colorectal neoplasia. Gastroenterology Sep 10 [Epub ahead of print]. *

• Hong WK, Sporn MB 1997 Recent advances in chemoprevention of cancer. Science 278: 1073-1077. *

• Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS; and Members of the UKCAP Consortium 2008 Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence. Int. J. Cancer 123: 586-593. *

• Huls G, Koornstra JJ, Kleibeuker JH 2003 Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362: 230-232. *

• Ikeda I, Tomimoto A, Wada K, Fujisawa T, Fujita K, Yonemitsu K, Nozaki Y, Endo H, Takahashi H, Yoneda M, Inamori M, Kubota K, Saito S, Nagashima Y, Nakagama H, Nakajima A 2007 5-Aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Clin. Cancer Res. 13: 6527-6531. *

• Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N 1998 The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett. 134: 129-139. *

• Imamura K, Lu J, Kaminishi M 2005 Roles of PPARs in carcinogenesis. Nippon Rinsho 63: 584-588.

• Ioffe Aiu 2005 Primary chemoprevention of colorectal cancer in cases of inflammatory bowel diseases. Lik. Sprava. 4: 45-48.

• Itzkowitz SH 2002 Cancer prevention in patients with inflammatory bowel disease. Gastroenterol. Clin. North Am. 31: 1133-1144.

• Itzkowitz SH, Harpaz N 2004 Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126: 1634-1648. *

• Jacoby RF, Cole CE, Hawk Et E, Lubet Ra R 2004 Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 127: 838-844. *

• Jalving M, Koornstra JJ, Jong S, Vries EG, Kleibeuker JH 2005 Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment. Pharmacol. Ther. 21: 321-339. *

• Jankowski JA, Hawk ET 2006 A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 101-111. *

• Janne PA, Mayer RJ 2000 Chemoprevention of colorectal cancer. N. Engl. J. Med. 342: 1960-1968. *

• Jeong WS, Keum YS, Chen C, Jain MR, Shen G, Kim JH, Li W, Kong AN 2005 Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells. J. Biochem. Mol. Biol. 38: 167-176. *

• Judge TA, Lewis JD, Lichtenstein GR 2002 Colonic dysplasia and cancer in inflammatory bowel disease. Gastrointest. Endosc. Clin. N. Am. 12: 495-523.

• Jung HY, Park SH, Yoo YD, Kim JS, Kim YH 2005 CDK2/4 regulate retinoic acid-induced G1 arrest in hepatocellular carcinoma cells. Hepatol. Res. 31: 143-152.

• Jurek D, Fleckl E, Marian B 2005 Bile acid induced gene expression in LT97 colonic adenoma cells. Food Chem. Toxicol. 43: 87-93. *

• Kahn MJ, Morrison DG 1997 Chemoprevention for colorectal carcinoma. Hematol. Oncol. Clin. North Am. 11: 779-794.

• Kakizoe T 2003 Chemoprevention of cancer - focusing on clinical trials. Jpn. J. Clin. Oncol. 33: 421-442. *

• Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H 2007 Synergistic growth inhibition by acyclic retinoid and vitamin K(2) in human hepatocellular carcinoma cells. Cancer Sci. 98: 431-437. *

• Karam SM, Hassan WM, John R 2005 Expression of retinoid receptors in multiple cell lineages in the gastric mucosae of mice and humans. J. Gastroenterol. Hepatol. 20: 1892-1899. *

• Karin M 2006 NF-kappaB and cancer: mechanisms and targets. Mol. Carcinog. 45: 355-361. *

• Karin M 2006 Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436. *

• Katiyar SK 2002 Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int. J. Oncol. 21: 1213-1222.

• Katoh M 2003 WNT2 and human gastrointestinal cancer (review). Int. J. Mol. Med. 12: 811-816.

• Keller JJ, Giardiello FM 2003 Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol. Ther. 2: S140-S149. *

• Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, Chen JG, Qian GS, Kuang SY, Jackson PE, Gange SJ, Jacobson LP, Munoz A, Groopman JD 2004 Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127 (5 Suppl. 2): S310-S318. *

• Khare S, Mustafi R, Cerda S, Yuan W, Jagadeeswaran S, Dougherty U, Tretiakova M, Samarel A, Cohen G, Wang J, Moore C, Wali R, Holgren C, Joseph L, Fichera A, Li YC, Bissonnette M 2008 Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr. Cancer 60: 389-400. *

• Kikuchi H, Murakami S, Suzuki S, Kudo H, Sassa S, Sakamoto S 2007 Chemopreventive effect of a vitamin D3 analog, alfacalcidol, on colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Drugs 18: 1183-1187.

• Kim ES, Hong WK, Khuri FR 2002 Chemoprevention of aerodigestive tract cancers. Annu. Rev. Med. 53: 223-243. *

• Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH 2006 Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 66: 12009-12018. *

• Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW 2004 Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 39: 518-527. *

• Kim YI 2003 Role of folate in colon cancer development and progression. J. Nutr. 133: 3731S-3739S. *

• Kim YI 2004 Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ. Mol. Mutagen. 44: 10-25.

• Kim YI 2007 Folate and colorectal cancer: an evidence-based critical review. Mol. Nutr. Food Res. 51: 267-292.

• Kishimoto Y, Morisawa T, Hosoda A, Shiota G, Kawasaki H, Hasegawa J 2002 Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane. J. Exp. Clin. Cancer Res. 21: 203-211.

• Kitiyakara T, Chapman RW 2008 Chemoprevention and screening in primary sclerosing cholangitis. Postgrad. Med. J. 84: 228-237.

• Kluth D, Banning A, Paur I, Blomhoff R, Brigelius-Flohe R 2007 Modulation of pregnane X receptor-and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds. Free Radic. Biol. Med. 42: 315-325.

• Kohli M, Yu J, Seaman C, Bardelli A, Kinzler KW, Vogelstein B, Lengauer C, Zhang L 2004 SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 101: 16897-16902. *

• Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, Mori H 2002 Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int. J. Cancer 101: 461-468. *

• Kojima S, Okuno M, Matsushima-Nishiwaki R, Friedman SL, Moriwaki H 2004 Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). Int. J. Oncol. 24: 797-805.

• Kolar SS, Barhoumi R, Callaway ES, Fan YY, Wang N, Lupton JR, Chapkin RS 2007 Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca2+ accumulation in colonocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G935-G943. *

• Kong AN, Owuor E, Yu R, Hebbar V, Chen C, Hu R, Mandlekar S 2001 Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab. Rev. 33: 255-271.

• Kowdley KV 2003 UDCA to prevent colon cancer in PSC. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 86. October 15-16. *

• Krishnan K, Brenner DE 1996 Chemoprevention of colorectal cancer. Gastroenterol. Clin. North Am. 25: 821-858.

• Kroll DJ, Shaw HS, Oberlies NH 2007 Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther. 6: 110-119.

• Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK 2003 Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J. Natl. Cancer Inst. 95: 206-214. *

• Kuzushita N, Rogers AB, Monti NA, Whary MT, Park MJ, Aswad BI, Shirin H, Koff A, Eguchi H, Moss SF 2005 p27(kip1) deficiency confers susceptibility to gastric carcinogenesis in Helicobacter pylori-infected mice. Gastroenterology 129: 1544-1556. *

• Lah JJ, Cui W, Hu KQ 2007 Effects and mechanisms of silibinin on human hepatoma cell lines. World J. Gastroenterol. 13: 5299-5305. *

• Lakatos L, Lakatos PL 2007 Medical therapy of inflammatory bowel diseases: ulcerative colitis. Orv. Hetil. 148: 1163-1170.

• Lamprecht SA, Lipkin M 2003 Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat. Rev. Cancer 3: 601-614. *

• Lanas A, Baron JA, Sandler RS, Horgan K, Bolognese J, Oxenius B, Quan H, Watson D, Cook TJ, Schoen R, Burke C, Loftus S, Niv Y, Ridell R, Morton D, Bresalier R 2007 Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 132: 490-497. *

• Lance P 2008 Chemoprevention for colorectal cancer: some progress but a long way to go. Gastroenterology 134: 341-343. *

• Lancon A, Hanet N, Jannin B, Delmas D, Heydel JM, Lizard G, Chagnon MC, Artur Y, Latruffe N 2007 Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos. 35: 699-703. *

• Langman M, Boyle P 1998 Chemoprevention of colorectal cancer. Gut 43: 578-585. *

• Lashner BA 2003 Clinical advances in ulcerative colitis. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland.

• Lashner BA 2008 Ulcerative colitis and colorectal cancer chemoprevention. Medscape (http://www.medscape.com/viewarticle/566843).

• Lazaridis KN, Gores GJ 2006 Primary sclerosing cholangitis and cholangiocarcinoma. Semin. Liver Dis. 26: 42-51. *

• Lebwohl M, Kathryn M 2006 New roles for systemic retinoids. J. Drugs Dermatol. 5: 406-409.

• Lee SJ, Lim KT 2008 Chemopreventive effect of plant originated glycoprotein on colitis-mediated colorectal cancer in A/J mice. J. Biomed. Sci. 15: 111-121. *

• Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ 2004 Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 53: 331-338. *

• Lewis J 2006 Biomarkers, surveillance strategies, chromoendoscopy medication-induced malignancies and chemoprevention (future). Inflamm. Bowel Dis. 12 Suppl. 3: S12.

• Lewis JD 2001 Ursodiol prevents UC-associated CRC. Gastroenterology 121: 491-492. *

• Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH 2008 The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br. J. Cancer 98: 1380-1388. *

• Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu T 2008 Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res. 68: 553-560. *

• Limburg PJ, Cerhan JR 2007 Aspirin chemoprevention for colorectal cancer: helpful, harmful, or still too soon to tell? Gastroenterology 133: 717-718. *

• Lindor KD 2006 Ursodeoxycholic acid for the treatment of PSC. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 85-86. *

• Liu W, Nakamura H, Tsujimura T, Cheng J, Yamamoto T, Iwamoto Y, Imanishi H, Shimomura S, Yamamoto T, Hirasawa T, Inagaki S, Nishiguchi S, Hada T 2006 Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci. 97: 768-773. *

• Loddenkemper C, Keller S, Hanski ML, Cao M, Jahreis G, Stein H, Zeitz M, Hanski C 2006 Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. Int. J. Cancer 118: 2750-2757. *

• Lu J, Zhang F, Zhao D, Hong L, Min J, Zhang L, Li F, Yan Y, Li H, Ma Y, Li Q 2008 ATRA-inhibited proliferation in glioma cells is associated with subcellular redistribution of beta-catenin via up-regulation of Axin. J. Neurooncol. 87: 271-277.

• Lu SC, Mato JM 2008 S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J. Gastroenterol. Hepatol. 23 Suppl. 1: S73-S77. *

• Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ 2008 Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int. J. Cancer Aug 19 [Epub ahead of print].

• Lupton JR 2004 Microbial degradation products influence colon cancer risk: the butyrate controversy. J. Nutr. 134: 479-482. *

• Macarthur M, Sharp L, Hold GL, Little J, El-Omar EM 2005 The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol. Biomarkers Prev. 14: 1613-1618. *

• MacFaul GR, Chapman RW 2005 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 21: 348-353.

• Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H 2005 Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 102: 14813-14818. *

• Manna S, Chakraborty T, Damodaran S, Samanta K, Rana B, Chatterjee M 2007 Protective role of fish oil (Maxepa) on early events of rat mammary carcinogenesis by modulation of DNA-protein crosslinks, cell proliferation and p53 expression. Cancer Cell Int. 7: 6.

• Marhenke S, Lamle J, Buitrago-Molina LE, Canon JM, Geffers R, Finegold M, Sporn M, Yamamoto M, Manns MP, Grompe M, Vogel A 2008 Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology 48: 487-496.

• Marotta F, Harada M, Goh KL, Lorenzetti A, Marandola P, Minelli E 2007 In vitro study on the mechanisms of action of a novel phytotherapeutic compound against human hepatoma cells. Ann. Hepatol. 6: 111-116. *

• Marotta F, Naito Y, Minelli E, Tajiri H, Bertuccelli J, Wu CC, Min CH, Hotten P, Fesce E 2003 Chemopreventive effect of a probiotic preparation on the development of preneoplastic and neoplastic colonic lesions: an experimental study. Hepatogastroenterology 50: 1914-1918.

• Marquez-Rosado L, Trejo-Solis MC, Garcia-Cuellar CM, Villa-Trevino S 2005 Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J. Hepatol. 43: 653-660. *

• Martinez JD, Stratagoules ED, LaRue JM, Powell AA, Gause PR, Craven MT, Payne CM, Powell MB, Gerner EW, Earnest DL 1998 Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr. Cancer 31: 111-118.

• Martínez ME, Jacobs ET, Ashbeck EL, Sinha R, Lance P, Alberts DS, Thompson PA 2007 Meat intake, preparation methods, mutagens, and colorectal adenoma recurrence. Carcinogenesis 28: 2019-2027. *

• Maruyama R, Aoki F, Toyota M, Sasaki Y, Akashi H, Mita H, Suzuki H, Akino K, Ohe-Toyota M, Maruyama Y, Tatsumi H, Imai K, Shinomura Y, Tokino T 2006 Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. 66: 4574-4583. *

• Mason JB 2002 Nutritional chemoprevention of colon cancer. Semin. Gastrointest. Dis. 13: 143-153.

• Mason JB, Levesque T 1996 Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology (Williston Park) 10: 1727-1736, 1742-1743.

• Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, Friedman SL, Kojima S 2001 Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res. 61: 7675-7682. *

• Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C, Hossain S, Ullman T 2005 Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 3: 1015-1021.

• Matusiak D, Benya RV 2007 CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J. Histochem. Cytochem. 55: 1257-1264.

• McGarr SE, Ridlon JM, Hylemon PB 2005 Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J. Clin. Gastroenterol. 39: 98-109.

• Milovic V, Turchanowa L 2003 Polyamines and colon cancer. Biochem. Soc. Trans. 31: 381-383. *

• Mirshafiey A, Khorramizadeh MR, Saadat F, Rehm BH 2004 Chemopreventive effect of M2000, a new anti-inflammatory agent. Med. Sci. Monit. 10: PI105-PI109. *

• Mollersen L, Paulsen JE, Olstorn HB, Knutsen HK, Alexander J 2004 Dietary retinoic acid supplementation stimulates intestinal tumour formation and growth in multiple intestinal neoplasia (Min)/+ mice. Carcinogenesis 25: 149-153. *

• Moon YJ, Wang X, Morris ME 2006 Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro 20: 187-210.

• Moore BC, Simmons DL 2000 COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. Curr. Med. Chem. 7: 1131-1144.

• Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R 2007 Chemoprevention of liver carcinogenesis with retinoids: basic and clinical aspects. Hepatol. Res. 37 Suppl. 2: S299-S302. *

• Mouzas IA, Papavassiliou E, Koutroubakis I 1998 Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate. Ital. J. Gastroenterol. Hepatol. 30: 421-425.

• Muller H, Plasilova M, Russell AM, Heinimann K 2003 Genetic predisposition as a basis for chemoprevention, surgical and other interventions in colorectal cancer. Recent Results Cancer Res. 163: 235-247.

• Munkholm P, Loftus Jr EV, Reinacher-Schick A, Kornbluth A, Mittmann U, Esendal B 2006 Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion 73: 11-19.

• Murray NR, Weems C, Chen L, Leon J, Yu W, Davidson LA, Jamieson L, Chapkin RS, Thompson EA, Fields AP 2002 Protein kinase C betaII and TGFbetaRII in omega-3 fatty acid-mediated inhibition of colon carcinogenesis. J. Cell. Biol. 157: 915-920. *

• Mutoh M, Niho N, Wakabayashi K 2006 Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol. Chem. 387: 381-385.

• Napoli JL 1999 Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim. Biophys. Acta 1440: 139-162. *

• Narayanan BA 2006 Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. Curr. Cancer Drug Targets 6: 711-727.

• Narayanan BA, Narayanan NK, Reddy BS 2001 Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells. Int. J. Oncol. 19: 1255-1262. *

• Narayanan BA, Narayanan NK, Simi B, Reddy BS 2003 Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res. 63: 972-979. *

• Narayanan NK, Narayanan BA, Reddy BS 2005 A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int. J. Oncol. 26: 785-792.

• Narisawa T 1998 An overview on chemoprevention of colorectal cancer. Nippon Geka Gakkai Zasshi 99: 362-367.

• Narisawa T, Fukaura Y, Takeba N, Nakai K 2002 Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats. Jpn. J. Cancer Res. 93: 143-150. *

• Nasir A, Fernandez PM, Chughtai OR, Kaiser HE 2002 COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms. In Vivo 16: 501-509.

• Nezbedova P, Brtko J 2004 1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action. Endocr. Regul. 38: 29-38. *

• Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K 2005 Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc. Natl. Acad. Sci. U.S.A. 102: 2970-2974. *

• Nixon DW 1995 Diet and chemoprevention of colon polyps and colorectal cancer. Semin. Surg. Oncol. 11: 411-415.

• Novoselov SV, Calvisi DV, Labunskyy VM, Factor VM, Carlson BA, Fomenko DE, Moustafa ME, Hatfield DL, Gladyshev VN 2005 Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 24: 8003-8011. *

• Nunez Martinez O, Clemente Ricote G, Garcia Monzon C 2003 Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases. Med. Clin. (Barc.) 121: 743-748.

• Ochsenkuhn T, Marsteller I, Hay U, Diebold J, Paumgartner G, Goke B, Sackmann M 2003 Does ursodeoxycholic acid change the proliferation of the colorectal mucosa? A randomized, placebo-controlled study. Digestion 68: 209-216.

• Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL, Moriwaki H 2004 Retinoids in cancer chemoprevention. Curr. Cancer Drug Targets 4: 285-298.

• Oshima M, Taketo MM 2002 COX inhibitor, suppression of polyposis, and chemoprevention. Nippon Yakurigaku Zasshi 120: 276-284.

• Oshima M, Taketo MM 2002 COX selectivity and animal models for colon cancer. Curr. Pharm. Des. 8: 1021-1034.

• Owen RW 1998 Dietary and chemopreventive strategies. Recent Results Cancer Res. 146: 195-213.

• Pang ML, E Murase J, Koo J 2008 An updated review of acitretin - a systemic retinoid for the treatment of psoriasis. Expert Opin. Drug Metab. Toxicol. 4: 953-964.

• Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD 2003 Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889-893. *

• Pari L, Tewas D, Eckel J 2008 Role of curcumin in health and disease. Arch. Physiol. Biochem. 114: 127-149.

• Park EY, Cho IJ, Kim SG 2004 Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res. 64: 3701-3713. *

• Park YS 2007 Cox-2 inhibitors in inflammatory bowel disease: friends or foes? Korean J. Gastroenterol. 50: 350-355.

• Pascale RM, Simile MM, De Miglio MR, Feo F 2002 Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 27: 193-198. *

• Pavan B, Biondi C, Dalpiaz A 2006 Nuclear retinoic acid receptor beta as a tool in chemoprevention trials. Curr. Med. Chem. 13: 3553-3563.

• Peleg II, Wilcox CM 2002 The role of eicosanoids, cyclooxygenases, and nonsteroidal anti-inflammatory drugs in colorectal tumorigenesis and chemoprevention. J. Clin. Gastroenterol. 34: 117-125.

• Platz EA, De Marzo AM 2004 Epidemiology of inflammation and prostate cancer. J. Urol. 171: S36-S40.

• Ponz D 2002 Prevention and chemoprevention of colorectal neoplasms. Dig. Liver Dis. 34: 59-69.

• Powell AA, Akare S, Qi W, Herzer P, Jean-Louis S, Feldman RA, Martinez JD 2006 Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity. BMC Cancer 6: 219. *

• Qiao D, Gaitonde SV, Qi W, Martinez JD 2001 Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. Carcinogenesis 22: 957-964. *

• Rae C, Langa S, Tucker SJ, Macewan DJ 2007 Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 104: 12790-12795. *

• Reddy BS 2000 The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol. Biomarkers Prev. 9: 239-247. *

• Reddy BS, Hirose Y, Cohen LA, Simi B, Cooma I, Rao CV 2000 Preventive potential of wheat bran fractions against experimental colon carcinogenesis: implications for human colon cancer prevention. Cancer Res. 60: 4792-4797. *

• Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV 2000 Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60: 293-297. *

• Reddy BS, Patlolla JM, Simi B, Wang SH, Rao CV 2005 Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res. 65: 8022-8027. *

• Reddy BS, Rao CV 2000 Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging 16: 329-334.

• Regazzi MB, Iacona I, Gervasutti C, Lazzarino M, Toma S 1997 Clinical pharmacokinetics of tretinoin. Clin. Pharmacokinet. 32: 382-402.

• Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W 2003 Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24: 443-451. *

• Reinacher-Schick A, Seidensticker F, Petrasch S, Reiser M, Philippou S, Theegarten D, Freitag G, Schmiegel W 2000 Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32: 245-254.

• Rex DK 2003 Colorectal cancer surveillance, screening, and colonoscopy. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland.

• Ricchi P, Pignata S, Iaffaioli RV, Daniele B 2003 Cyclo-oxygenase inhibition in colorectal adenomas and cancer. J. Clin. Gastroenterol. 37: 281-287.

• Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM 2003 Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br. J. Cancer 88: 803-807. *

• Ricciardiello L, Roda E, Bazzoli F 2002 Chemoprevention in colorectal neoplasias: what is practical and feasible? Dig. Dis. 20: 70-72.

• Rigas B 2007 The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr. Opin. Gastroenterol. 23: 55-59.

• Ritland SR, Leighton JA, Hirsch RE, Morrow JD, Weaver AL, Gendler SJ 1999 Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Clin. Cancer Res. 5: 855-863. *

• Robertson DJ, Greenberg ER, Beach M, Sandler RS, Ahnen D, Haile RW, Burke CA, Snover DC, Bresalier RS, McKeown-Eyssen G, Mandel JS, Bond JH, Van Stolk RU, Summers RW, Rothstein R, Church TR, Cole BF, Byers T, Mott L, Baron JA 2005 Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 129: 34-41. *

• Rose DP, Connolly JM 1999 Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol. Ther. 83: 217-244. *

• Rougier P, Mitry E 2003 Epidemiology, treatment and chemoprevention in colorectal cancer. Ann. Oncol. 14 Suppl. 2: ii3-5. *

• Roy H 2001 Chemoprevention adds up. Am. J. Gastroenterol. 96: 278. *

• Roy HK, Karolski WJ, Ratashak A 2001 Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int. J. Cancer 92: 609-615. *

• Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA, Riddell RH, Rutter MD, Ullman TA, Velayos FS, Itzkowitz S; 5-ASA in Colorectal Cancer Prevention Meeting Group 2008 Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm. Bowel Dis. 14: 265-274. *

• Rubin DT, Lashner BA 2005 Will a 5-ASA a day keep the cancer (and dysplasia) away? Am. J. Gastroenterol. 100: 1354-1356. *

• Rubin DT, Losavio A, Yadron N, Huo D, Hanauer SB 2006 Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin. Gastroenterol. Hepatol. 4: 1346-1350.

• Rubin DT, Parekh N 2006 Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr. Treat. Options Gastroenterol. 9: 211-220.

• Ryan BM, Russel MG, Langholz E, Stockbrugger RW 2003 Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am. J. Gastroenterol. 98: 1682-1687. *

• Sainis I, Vareli K, Karavasilis V, Briasoulis E 2008 PPARgamma: the portrait of a target ally to cancer chemopreventive agents. PPAR Res. 2008: 436489. *

• Sandborn WJ 2006 Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev. Gastroenterol. Disord. 6: 97-105.

• Santini DL, Rigas B, Shiff SJ 1999 Role of diet and NSAIDs in the chemoprevention of colorectal cancer. J. Assoc. Acad. Minor Phys. 10: 68-76.

• Schatzkin A, Kelloff G 1995 Chemo- and dietary prevention of colorectal cancer. Eur. J. Cancer 31A: 1198-1204. *

• Scheppach W, Weiler F 2004 The butyrate story: old wine in new bottles? Curr. Opin. Clin. Nutr. Metab. Care 7: 563-567.

• Schottenfeld D, Beebe-Dimmer J 2006 Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin. 56: 69-83. *

• Schreibman I, Regev A 2006 Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management. MedGenMed. 8: 30.

• Schrumpf E, Jorgensen KK, Boberg KM 2006 Primary sclerosing cholangitis, inflammatory bowel disease and treatment options. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 15-16. *

• Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J 2008 PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29: 1407-1414. *

• Sedjo RL, Ranger-Moore J, Foote J, Craft NE, Alberts DS, Xu MJ, Giuliano AR 2004 Circulating endogenous retinoic acid concentrations among participants enrolled in a randomized placebo-controlled clinical trial of retinyl palmitate. Cancer Epidemiol. Biomarkers Prev. 13: 1687-1692. *

• Serfaty L, Poupon R 2004 Ursodeoxycholic acid and colorectal carcinogenesis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 76-77. June 18-19. *

• Serini S, Trombino S, Oliva F, Piccioni E, Monego G, Resci F, Boninsegna A, Picci N, Ranelletti FO, Calviello G 2008 Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis 13: 1172-1183.

• Sertznig P, Seifert M, Tilgen W, Reichrath J 2007 Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J. Cell. Physiol. 212: 1-12. *

• Sertznig P, Seifert M, Tilgen W, Reichrath J 2008 Cross-regulation of peroxisome proliferator-activated receptor- (PPAR) and vitamin D receptor-signaling pathways in melanoma cells. Exp. Dermatol. 17: 626-627.

• Setchell KD, Brown N 2006 Ursodeoxycholic acid-disulfate (SUDCA) - a potent chemopreventive agent against colon cancer. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 79. *

• Shah SA, Looby E, Volkov Y, Long A, Kelleher D 2005 Ursodeoxycholic acid inhibits translocation of protein kinase C in human colonic cancer cell lines. Eur. J. Cancer 41: 2160-2169. *

• Shanahan F 2003 Review article: colitis-associated cancer - time for new strategies. Aliment. Pharmacol. Ther. 18 Suppl. 2: 6-9. *

• Sharma RA, Gescher AJ, O'Byrne KJ, Steward WP 2001 Familiar drugs may prevent cancer. Postgrad. Med. J. 77: 492-497. *

• Shaukat A, Scouras N, Schunemann HJ 2005 Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am. J. Gastroenterol. 100: 390-394. *

• Shiota G, Tsuchiya H, Hoshikawa Y 2006 The liver as a target organ of retinoids. Hepatol. Res. 36: 248-254.

• Simopoulos AP 2004 The traditional diet of Greece and cancer. Eur. J. Cancer Prev. 13: 219-230.

• Singh AK, Trotman BW 1998 Use and safety of aspirin in the chemoprevention of colorectal cancer. J. Assoc. Acad. Minor Phys. 9: 40-44.

• Singh J, Kulkarni N, Kelloff G, Reddy BS 1994 Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 15: 1317-1323.

• Sirica AE 2005 Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15. *

• Sjoqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Lofberg R 2004 Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res. 24: 3121-3127.

• Smalley WE, DuBois RN 1997 Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39: 1-20.

• So PL, Fujimoto MA, Epstein EH Jr 2008 Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol. Cancer Ther. 7: 1275-1284.

• Song J, Sohn KJ, Medline A, Ash C, Gallinger S, Kim YI 2000 Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/- mice. Cancer Res. 60: 3191-3199. *

• Song WL, Lawson JA, Reilly D, Rokach J, Chang CT, Giasson B, Fitzgerald GA 2008 Neurofurans: novel indices of oxidant stress derived from docosahexaenoic acid. J. Biol. Chem. 283: 6-16. *

• Spychalski M, Dziki L, Dziki A 2007 Chemoprevention of colorectal cancer - a new target needed? Colorectal Dis. 9: 397-401. *

• Stoehlmacher J, Lenz HJ 2003 Cyclooxygenase-2 inhibitors in colorectal cancer. Semin. Oncol. 30: 10-16.

• Stoll BA 2002 Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention. Eur. J. Cancer Prev. 11: 319-325.

• Stone WL, Krishnan K, Campbell SE, Qui M, Whaley SG, Yang H 2004 Tocopherols and the treatment of colon cancer. Ann. N. Y. Acad. Sci. 1031: 223-233.

• Strul H, Arber N 2000 Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. Isr. Med. Assoc. J. 2: 695-702.

• Sudbo J 2003 Chemoprevention: treatment of persons at high risk of cancer. Tidsskr. Nor. Laegeforen. 123: 1514-1517.

• Sugiyama Y, Farrow B, Murillo C, Li J, Watanabe H, Sugiyama K, Evers BM 2005 Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology 128: 480-486. *

• Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ 2008 Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 68: 2912-2919.

• Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV 2004 Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol. Cancer Ther. 3: 215-221. *

• Swift CB, Hays JL, Petty WJ 2008 Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy. Endocr. Metab. Immune Disord. Drug Targets 8: 47-50.

• Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M 2006 Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br. J. Cancer 95: 889-895. *

• Takayama T, Miyanishi K, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Kogawa T, Abe T, Niitsu Y 2005 Aberrant crypt foci: detection, gene abnormalities, and clinical usefulness. Clin. Gastroenterol. Hepatol. 3: S42-S45. *

• Talwalkar JA, Lindor KD 2002 Sclerosing cholangitis. Curr. Opin. Gastroenterol. 18: 372-377.

• Tammali R, Ramana KV, Srivastava SK 2007 Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells. Cancer Lett. 252: 299-306. *

• Tanabe K, Utsunomiya H, Tamura M, Niikura H, Takano T, Yoshinaga K, Nagase S, Suzuki T, Ito K, Matsumoto M, Hayashi S, Yaegashi N 2008 Expression of retinoic acid receptors in human endometrial carcinoma. Cancer Sci. 99: 267-271. *

• Tang CL 2003 Chemoprevention of colorectal cancer - experimental approach and clinical applications. Ann. Acad. Med. Singapore 32: 169-175.

• Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, Burt R, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Shike M, Weissfeld J, Schatzkin A; Polyp Prevention Study Group 2003 Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 14: 403-411. *

• Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R 2007 Identification of the retinoic acid inducible Gprc5a as a new lung tumor suppressor gene. J. Natl. Cancer Inst. 99: 1668-1682. *

• Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, Schinazi RD, Korba BE, Cote PJ, Gerin JL 2004 Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127 (5 Suppl. 2): S283-S293. *

• Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT 2007 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13: 367-371. *

• Terhaar Sive Droste JS, Tuynman JB, Van Dullemen HM, Mulder CJ 2006 Chemoprevention for colon cancer: new opportunities, fact or fiction? Scand. J. Gastroenterol. Suppl. 243: 158-164. *

• Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S 2002 Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62: 5196-5203. *

• Thomson A 2006 Chemoprevention of colorectal cancer in ulcerative colitis. Intern. Med. J. 36: 540. *

• Thorne J, Campbell MJ 2008 The vitamin D receptor in cancer. Proc. Nutr. Soc. 67: 115-127.

• Toit-Kohn JL, Louw L, Engelbrecht AM 2008 Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways. J. Nutr. Biochem. May 12 [Epub ahead of print]. *

• Tokar EJ, Ancrile BB, Ablin RJ, Webber MM 2006 Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer. J. Exp. Ther. Oncol. 5: 323-333.

• Tokar EJ, Webber MM 2005 Chemoprevention of prostate cancer by cholecalciferol (vitamin D(3)): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin. Exp. Metastasis 22: 265-273. *

• Travis S 2005 Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 7: 475-484.

• Ullman TA 2005 Preventing neoplastic progression in ulcerative colitis. J. Clin. Gastroenterol. 39: S66-S69.

• Ullman TA 2002 Cancer in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 5: 163-171.

• Ullman TA, Croog V, Maratchi L, Jaffe D, Itzkowitz SH 2003 Ursodeoxycholic acid for chemoprevention in ulcerative colitis and primary sclerosing cholangitis: a retrospective cohort study. Am. J. Gastroenterol. 98: S258. *

• Umar A, Viner JL, Hawk ET 2001 The future of colon cancer prevention. Ann. N. Y. Acad. Sci. 952: 88-108.

• Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET 2002 Chemoprevention of colorectal carcinogenesis. Int. J. Clin. Oncol. 7: 2-26. *

• Urbanska K, Pannizzo P, Grabacka M, Croul S, Del Valle L, Khalili K, Reiss K 2008 Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int. J. Cancer 123: 1015-1024. *

• Vainio H, Miller AB 2003 Primary and secondary prevention in colorectal cancer. Acta Oncol. 42: 809-815.

• Vaisman N, Arber N 2002 The role of nutrition and chemoprevention in colorectal cancer: from observations to expectations. Best Pract. Res. Clin. Gastroenterol. 16: 201-217.

• van Beelen VA, Aarts JM, Reus A, Mooibroek H, Sijtsma L, Bosch D, Rietjens IM, Alink GM 2006 Differential induction of electrophile-responsive element-regulated genes by n-3 and n-6 polyunsaturated fatty acids. FEBS Lett. 580: 4587-4590. *

• van Bodegraven AA, Mulder CJ 2006 Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J. Gastroenterol. 12: 6115-6123. *

• Van Ginderachter JA, Movahedi K, Van den Bossche J, De Baetselier P 2008 Macrophages, PPARs, and cancer. PPAR Res. 2008: 169414. *

• van Gorkom BA, van der Meer R, Boersma-van Ek W, Termont DS, de Vries EG, Kleibeuker JH 2002 Changes in bile acid composition and effect on cytolytic activity of fecal water by ursodeoxycholic acid administration: a placebo-controlled cross-over intervention trial in healthy volunteers. Scand. J. Gastroenterol. 37: 965-971. *

• Veeramachaneni NK, Lin L, Pippin JA, Winslow ER, Drebin JA 2003 Doxycycline and indomethacin synergistically downregulate beta-catenin signaling and inhibit colon cancer cell growth. J. Surg. Res. 114: 251-252.

• Velayos FS, Terdiman JP, Walsh JM 2005 Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. 100: 1345-1353. *

• Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, Deleo AB 2007 Identification of human aldehyde dehydrogenase 1 family member a1 as a novel CD8+ T-cell defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 67: 10538-10545. *

• Wali RK, Frawley BP Jr, Hartmann S, Roy HK, Khare S, Scaglione-Sewell BA, Earnest DL, Sitrin MD, Brasitus TA, Bissonnette M 1995 Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res. 55: 5257-5264. *

• Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, Wen M, Ramaswamy A, Joseph L, Sitrin M, Brasitus T, Bissonnette M 2002 Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol. Biomarkers Prev. 11: 1653-1662.

• Wali RK, Stoiber D, Nguyen L, Hart J, Sitrin MD, Brasitus T, Bissonnette M 2002 Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol. Biomarkers Prev. 11: 1316-1321. *

• Wallace HM, Fraser AV 2004 Inhibitors of polyamine metabolism: review article. Amino Acids 26: 353-365. *

• Wang D, Dubois RN 2008 Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res. 2008: 931074. *

• Wang L, Levin MS 2005 Suppression of FGF signaling: a putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma. Gastroenterology 128: 228-231. *

• Wang XJ, Hayes JD, Henderson CJ, Wolf CR 2007 Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc. Natl. Acad. Sci. U.S.A. 104: 19589-19594. *

• Wang Y, Yao R, Maciag A, Grubbs CJ, Lubet RA, You M 2006 Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide. Mol. Cancer Ther. 5: 1060-1072. *

• Watson AJ 1998 Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol. Histopathol. 13: 591-597.

• Williams D, Verghese M, Walker LT, Boateng J, Shackelford L, Chawan CB 2007 Flax seed oil and flax seed meal reduce the formation of aberrant crypt foci (ACF) in azoxymethane-induced colon cancer in Fisher 344 male rats. Food Chem. Toxicol. 45: 153-159. *

• Wilson JM, Coletta PL, Cuthbert RJ, Scott N, Maclennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R, Hull MA 2005 Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129: 1485-1503. *

• Winawer SJ 2005 Screening of colorectal cancer. Surg. Oncol. Clin. N. Am. 14: 699-722.

• Wolf JM, Rybicki LA, Lashner BA 2005 The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 22: 783-788. *

• Wong LL, Tsai N, Limm W, Wong L 2004 Liver transplant for hepatocellular cancer: a treatment for the select few. Clin. Transplant. 18: 205-210.

• Wu K, Dupre E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PH 2006 Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res. Treat. 96: 147-157. *

• Wu W, Celestino J, Milam MR, Schmeler KM, Broaddus RR, Ellenson LH, Lu KH 2008 Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Int. J. Gynecol. Cancer 18: 329-338.

• Xie J, Itzkowitz SH 2008 Cancer in inflammatory bowel disease. World J. Gastroenterol. 14: 378-389. *

• Xu L, Han C, Wu T 2006 A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J. Biol. Chem. 281: 33982-33996. *

• Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H, Kojima S, Weinstein IB, Moriwaki H 2007 Synergistic effects of RXRalpha and PPARgamma ligands to inhibit growth in human colon cancer cells - phosphorylated RXRalpha is a critical target for colon cancer management. Gut 56: 1557-1563.

• Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, Murawaki Y, Hashiguchi K, Kanbe T, Saeki T, Ichiba M, Tanabe Y, Yoshida Y, Morino S, Kurimasa A, Usuda N, Yamazaki H, Kunisada T, Ito H, Murawaki Y, Shiota G 2004 Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 40: 366-375. *

• Yang IA, Fong KM, Zimmerman PV, Holgate ST, Holloway JW 2008 Genetic susceptibility to the respiratory effects of air pollution. Thorax 63: 555-563.

• Yang K, Lamprecht SA, Shinozaki H, Fan K, Yang W, Newmark HL, Kopelovich L, Edelmann W, Jin B, Gravaghi C, Augenlicht L, Kucherlapati R, Lipkin M 2008 Dietary calcium and cholecalciferol modulate cyclin D1 expression, apoptosis, and tumorigenesis in intestine of adenomatous polyposis coli1638N/+ mice. J. Nutr. 138: 1658-1663. *

• Yasui Y, Kim M, Tanaka T 2008 PPAR ligands for cancer chemoprevention. PPAR Res. 2008: 548919. *

• Yee LD, Young DC, Rosol TJ, Vanbuskirk AM, Clinton SK 2005 Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. J. Nutr. 135: 983-988. *

• Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopleovich L, Glazer RI 2005 Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 65: 3950-3957. *

• Yoon JH, Gores GJ 2003 Diagnosis, staging, and treatment of cholangiocarcinoma. Curr. Treat. Options Gastroenterol. 6: 105-112.

• Yu J, Hui AY, Chu ES, Cheng AS, Go MY, Chan HL, Leung WK, Cheung KF, Ching AK, Chui YL, Chan KK, Sung JJ 2007 Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. Gut 56: 991-999. *

• Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Rocken C, Malfertheiner P, Farrell GC 2006 Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43: 134-143. *

• Yuan CJ, Mandal AK, Zhang Z, Mukherjee AB 2000 Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs. Cancer Res. 60: 1084-1091. *

• Zhang DD 2006 Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 38: 769-789. *

• Zhang Y, Yao S, Li J 2006 Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action. Proc. Nutr. Soc. 65: 68-75. *

• Zhou C, Poulton EJ, Grun F, Bammler TK, Blumberg B, Thummel KE, Eaton DL 2007 The dietary isothiocyanate, sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor (SXR). Mol. Pharmacol. 71: 220-229. *

• Zhou GD, Popovic N, Lupton JR, Turner ND, Chapkin RS, Donnelly KC 2005 Tissue-specific attenuation of endogenous DNA I-compounds in rats by carcinogen azoxymethane: possible role of dietary fish oil in colon cancer prevention. Cancer Epidemiol. Biomarkers Prev. 14: 1230-1235. *

• Zisman TL, Rubin DT 2008 Colorectal cancer and dysplasia in inflammatory bowel disease. World J. Gastroenterol. 14: 2662-2669. *

• Zouboulis CC 2001 Retinoids - which dermatological indications will benefit in the near future? Skin Pharmacol. Appl. Skin Physiol. 14: 303-315.

• Zucker SD, Horn PS, Sherman KE 2004 Serum bilirubin levels in the U.S. population: Gender effect and inverse correlation with colorectal cancer. Hepatology 40: 827-835. *

Number of references = 425

www psc-literature.org